Open access to peptides

1. At a Glance

• Peptides are short chains of amino acids linked by peptide bonds. In this news item they are unapproved therapeutic molecules that the U.S. now allows to be compounded (custom-prepared) by licensed pharmacies and physicians [1].
• The trigger is a U.S. "enforcement discretion policy" from Health Secretary Robert F. Kennedy Jr., published in the Federal Register. It lets six peptides be compounded without fear of FDA reprisal [1].
• Why it matters for UPSC: it shows a regulator choosing not to enforce rather than formally approving a drug. That links to drug regulation, patient safety, the evidence base for medicines, and India's own regulator (CDSCO), which handles similar "grey-market" drugs, including peptides sold for wellness and gym use [GK — unverified].

2. Why in the News

• October 2026: RFK Jr. advanced a policy letting licensed U.S. pharmacies and physicians compound certain unapproved peptides while regulators decide whether to formally permit them in compounded medicines [1].
• The policy covers six peptides, including BPC-157 and TB-500, which together are popularly called the "Wolverine stack" [1].
• Reported by Reuters and carried in The Hindu, Chennai print edition, 30 October 2026, p. 42 [1].

3. Background & Evolution

• Compounding means a pharmacist or physician prepares a medicine tailored to one patient, for example by changing its strength, form or ingredients. Compounded drugs are normally not FDA-approved individually [GK — unverified].
• U.S. legal base: Sections 503A (pharmacy compounding) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. These were strengthened by the Drug Quality and Security Act, 2013, passed after the 2012 New England Compounding Center meningitis outbreak [GK — unverified].
• Bulk substances allowed for compounding are sorted into FDA "categories". Several peptides, BPC-157 among them, had earlier been placed in a restricted category over safety concerns [GK — unverified].
• 2026: the enforcement discretion policy allows compounding to go ahead pending a formal rule-making decision [1].

4. Core Static Facts

Item	Fact
Policy name	"Enforcement discretion policy" [1]
Issued by	U.S. Health Secretary Robert F. Kennedy Jr. (Department of Health and Human Services, HHS) [1]
Published in	Federal Register, the U.S. government's official gazette for rules and notices [1]
Agency not enforcing	FDA (U.S. Food and Drug Administration) [1]
Who may compound	Licensed pharmacies and physicians [1]
Number of peptides	Six [1]
Named peptides	BPC-157, TB-500 [1]
Popular name	"Wolverine stack", from claims about tissue healing and recovery [1]
Legal status	Peptides stay unapproved; formal permission is still under consideration [1]
Definitions	Peptide: generally fewer than about 50 amino acids; longer chains are proteins. BPC-157: "Body Protection Compound", a synthetic fragment derived from a gastric protein. TB-500: a synthetic analogue of thymosin beta-4 [GK — unverified]
Indian parallel	Drugs and Cosmetics Act, 1940; regulator CDSCO under the Ministry of Health & Family Welfare, headed by the DCGI [GK — unverified]

5. Multi-Dimensional Analysis

Legal / Governance

• Enforcement discretion is not legalisation. It is a decision not to prosecute while the formal process continues [1].
• It skips the usual evidence-led approval route. This raises questions of regulatory capture and politicisation of science agencies [S1 for the policy; analysis is the note's own].
• Because a minister can do this by policy, a later administration can also reverse it, which leaves industry and patients uncertain.

Scientific / Technological

• Peptide therapeutics are a fast-growing class; GLP-1 agonists such as semaglutide are peptides [GK — unverified].
• BPC-157 and TB-500 have mostly animal or preclinical data and lack robust human trials [GK — unverified].
• Compounded products face weaker checks on purity, sterility and dose consistency than approved drugs.

Ethical / Public Health

• The "right to try" and patient autonomy pull against the precautionary principle.
• The policy could widen use for wellness, anti-ageing and sports recovery among people who are not ill.
• These peptides are on the WADA Prohibited List (S0 / S2 classes), which raises sports-integrity concerns [GK — unverified].

Economic

• Opens a market for compounding pharmacies and telehealth "wellness" clinics.
• Weakens the incentive to pay for costly approval trials, since products can sell without approval.

Geopolitical / Comparative (India angle)

• U.S. regulatory signals shape demand worldwide. India is a major supplier of APIs (active pharmaceutical ingredients) and generics, so demand for peptide APIs could rise.
• India regulates new drugs under the New Drugs and Clinical Trials Rules, 2019. Unapproved peptides sold online fall into a grey zone that needs CDSCO and State Drug Controller enforcement [GK — unverified].

6. Recent Developments (last 12–18 months)

• October 2026: the enforcement discretion policy appeared in the Federal Register and enabled compounding of six peptides, including BPC-157 and TB-500 [1].
• Pending: the regulatory decision on whether to formally permit these peptides in compounded medicines [1].
• Search budget was used up without retrieving any other dated developments; none are listed rather than guessed.

7. Prelims Hooks

• The "enforcement discretion policy" on peptides was issued by U.S. Health Secretary Robert F. Kennedy Jr. [1]
• It was published in the Federal Register [1].
• It enables compounding of six peptides [1].
• BPC-157 + TB-500 are together called the "Wolverine stack" [1].
• Permitted actors: licensed pharmacies and physicians, not manufacturers marketing approved drugs [1].
• The peptides remain unapproved; the policy only shields compounders from FDA action [1].
• Compounding means preparing a customised medicine for an individual patient.
• Peptide vs protein: both are amino-acid chains linked by peptide (amide) bonds; peptides are the shorter ones [GK — unverified].
• Insulin and GLP-1 agonists are examples of approved peptide drugs [GK — unverified].
• India's drug regulator is CDSCO under MoHFW, not the Department of Pharmaceuticals [GK — unverified].
• India's parent drug law is the Drugs and Cosmetics Act, 1940 [GK — unverified].

8. Who Must Prove the Drug Works — and Why This Policy Flips It

• In normal approval, the company must prove the drug is safe and works
• A drug maker runs human trials and shows the results to the regulator before selling.
• Under enforcement discretion, the peptides stay unapproved, but pharmacies can still sell them [1].

• Nobody has to prove anything first. If harm appears, the regulator has to find it later.

• For BPC-157, most of the evidence comes from rats

• Research on BPC-157 is still mainly animal work. One example is a 2026 study in Scientific Reports on leg-tissue injury in rats [8].
• A rat study can show a molecule is worth testing. It cannot tell a doctor the right human dose or the long-term side effects.

• So the "Wolverine stack" claims of fast healing [1] are running ahead of the science.

• A pending decision can stay pending for years

• The policy works only "pending" a formal decision [1]. While that decision waits, use keeps spreading.
• The longer it waits, the harder it becomes to withdraw a product that thousands of people already use. This happens even if the safety data never arrives.

9. The Best Argument for Open Access, and Where It Falls Short

• The strongest case: people are buying these peptides anyway
• Supporters say these peptides are already sold widely online by unlicensed sellers.
• Moving sales to licensed pharmacies and physicians [1] puts a trained professional between the buyer and the product.

• Fair point. A licensed pharmacy is safer than an anonymous website. The WHO estimates that about 1 in 10 medical products in low- and middle-income countries is substandard or falsified [4].

• What the argument gets right

• Banning on paper does not stop demand. It only pushes buyers to sources that nobody inspects.

• Harm reduction (making risky behaviour less dangerous instead of only forbidding it) is a real public-health tool.

• Where it falls short

• A licensed pharmacy can make sure the vial holds what the label says. It cannot make sure the molecule actually works.
• Quality (is it pure?) and efficacy (does it work?) are two different questions. Only clinical trials answer the second.

• A government-backed route also makes the product look trustworthy. That can pull in healthy people who would never have bought from a shady website.

• Honest verdict: the policy deals with the purity problem. It leaves the evidence problem open, and it may grow the market before that problem is solved.

10. Why India's Online Drug Market Leaves These Peptides Unchecked

• India's rules for online pharmacies are still only a draft after eight years
• The Health Ministry published draft e-pharmacy rules as G.S.R. 817(E) on 28 August 2018. They would amend the Drugs and Cosmetics Rules, 1945 [6].
• The ministry said it could not set a date to finalise them, because the matter is subjudice (pending before the courts) in several High Courts [6].

• Result: no clear licence regime covers a website that ships peptide vials to a gym-goer.

• The replacement law is also stuck

• The Drugs, Medical Devices and Cosmetics Bill, 2022 would let the government set conditions for selling drugs online [7].

• Until it is passed, the 1940 Act, written long before the internet, remains the base law.

• Quality surveys check listed medicines, not wellness peptides

• India's largest national drug survey, run by the National Institute of Biologicals, tested 47,954 samples. It found 3.16% not of standard quality (NSQ, meaning the drug fails a quality test) and 0.0245% spurious (fake) [2].
• These samples came from known supply chains: retail shops, government stores, ports [2].

• Peptides sold online for "recovery" are not part of that chain, so no survey captures how good or bad they are.

• Fewer inspectors than the market needs

• CDSCO's sanctioned posts rose from 111 in 2008 to 492 in January 2021 [3].

• That is still a small national staff. Most retail and online checks depend on State Drug Controllers, whose capacity varies from state to state.

• The global problem is growing

• WHO says countries spend about US$30.5 billion a year on substandard and falsified medical products [5].
• In February 2025, WHO reported a nearly 60% rise in reported incidents over two years [9].
• A US signal that raises peptide demand worldwide feeds straight into this weak spot.

11. What India's Regulators Can Do Before the Demand Arrives

• MoHFW should finalise the 2018 e-pharmacy rules
• The draft already covers registration, inspection and an advertising ban [6].

• Finalising it would give CDSCO a legal handle on websites selling unapproved peptides, which today work in a grey zone.

• Parliament should pass the online-sale power in the 2022 Bill

• The Drugs, Medical Devices and Cosmetics Bill, 2022 lets the government set conditions for online drug sales [7].

• Peptides and other "wellness injectables" could then be named as a class needing a prescription.

• CDSCO should run a targeted survey of online peptides, using the NIB survey as the model

• The national survey showed India can test nearly 48,000 samples across the country [2].

• A smaller version that buys peptides from websites and gyms would show whether the problem is mislabelled content, contamination or wrong dose.

• Report failures to WHO's global surveillance system

• WHO runs a global platform for reporting substandard and falsified products [9].

• Feeding Indian peptide test failures into it helps other countries trace where bad batches come from. That matters because India is a major ingredient supplier.

• Keep enforcement discretion out of India's toolkit for unproven drugs

• India's New Drugs and Clinical Trials Rules, 2019 require evidence before approval.
• The US case shows that "not enforcing for now" can quietly become permission. A rule that gives no such ministerial shortcut keeps the burden of proof on the seller.

12. Anchors for Answers

• Data: National drug survey (NIB, for MoHFW): 47,954 samples; 3.16% not of standard quality, 0.0245% spurious [2]
• Data: WHO: about 1 in 10 medical products in low- and middle-income countries is substandard or falsified (10.5% failure rate, 88 countries) [4]; about US$30.5 billion spent on them each year [5]
• Data: CDSCO sanctioned posts rose from 111 (2008) to 492 (January 2021) [3]
• Report/Committee: WHO global study on substandard and falsified medical products, 2017 [4]
• Law/Case: Draft e-pharmacy rules, G.S.R. 817(E), 28 August 2018 (amending Drugs and Cosmetics Rules, 1945); still unfinalised because the matter is pending in High Courts [6]
• Law/Case: Drugs, Medical Devices and Cosmetics Bill, 2022: gives power to set conditions for online sale of drugs [7]
• Comparison: United States: an HHS enforcement discretion policy lets six unapproved peptides be compounded while the formal decision is pending [1]. India has no matching shortcut; new drugs go through the New Drugs and Clinical Trials Rules, 2019

13. Mains Relevance

• GS-II: Health; Issues relating to development and management of the Health sector; Statutory and regulatory bodies.
• GS-III: Science and Technology: developments and their applications (biotechnology, pharmaceuticals).
• GS-IV: Ethics in public administration; the precautionary principle; conflict of interest.
• Question stems: 1. Regulatory 'enforcement discretion' can widen patient access but may erode evidence-based medicine. Critically examine with reference to recent U.S. policy on compounded peptides. 2. Discuss the regulatory challenges posed by peptide therapeutics and wellness drugs sold online in India. Suggest reforms to the drug-regulatory framework. 3. Balancing patient autonomy against public-health safeguards is a core ethical dilemma for drug regulators. Discuss.

14. Related Topics to Study Next

• CDSCO and the Drugs and Cosmetics Act, 1940: India's equivalent of the FDA's approval role.
• New Drugs and Clinical Trials Rules, 2019: India's pathway for approving new drugs.
• Proposed Drugs, Medical Devices and Cosmetics Bill: the planned replacement for the 1940 Act.
• GLP-1 drugs (semaglutide, tirzepatide): the best-known peptide drugs; patent expiry and Indian generics.
• Biologics vs biosimilars: how regulation differs for large-molecule drugs.
• WADA / NADA and the Prohibited List: doping concerns over performance-enhancing peptides.
• Online pharmacies and e-pharmacy regulation in India: the channel through which unapproved drugs spread.
• Right to Try / compassionate use: comparable routes to unapproved therapies.

15. NCERT Concepts to Revise

• Regulatory capture (Polity): The note flags that skipping evidence-based approval raises fears of regulators serving industry or political interests, not the public.
• Precautionary principle (Economy): Patient access to unproven peptides is weighed against the principle of acting cautiously when safety evidence is incomplete.
• Patent (Economy): Skipping approval trials weakens incentives for firms to invest in proving drugs, which patents normally reward.
• Governance (Polity): Enforcement discretion shows how rules are applied or relaxed by officials, not only how laws are written.
• Outsourcing (Economy): Outsourcing facilities (503B) are one U.S. legal route for compounding, and India is a major drug-ingredient supplier.

16. Common Errors / Trap Areas

• Enforcement discretion is not approval. The peptides are still unapproved [1].
• Wrong actor: the policy came from the HHS Secretary, not an FDA approval decision [1].
• Wrong count: six peptides, not two. BPC-157 and TB-500 are only the best-known [1].
• Compounding is not generic manufacturing. Compounding is patient-specific; generics are mass-produced, approved copies.
• Indian regulator: CDSCO sits under MoHFW, not the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers [GK — unverified].